Hims & Hers (HIMS) is down -5.0%, or -$1.55 to $29.50.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers falls -6.1%
- Morgan Stanley says Hims branded tirzepatide margins likely well below compounds
- Sell Rating for Hims & Hers Health Due to High Pricing and Limited Market Penetration of New Offerings
- Cautious Outlook on Hims & Hers Health Amid Expansion and Margin Concerns
- Citi sees high price of Tirzepatide on Hims & Hers being ‘prohibitive’
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue